Tag Archives: request

SolarCity’s Losses Expected To Deepen Amid Slow Rooftop Bookings

No. 1 residential installer SolarCity ( SCTY ) was poised late Monday for its fourth consecutive quarter of double-digit sales growth, but its losses were expected to widen again. The consensus of 18 analysts polled by Thomson Reuters expects SolarCity to report $108.4 million in sales, up 61%. The company, however, is seen posting an adjusted loss of $2.31 a share vs. a $1.52 per-share loss in the year-earlier quarter. SolarCity’s losses have ballooned from below 50 cents in 2013. Previously, SolarCity said it expected its adjusted loss to come in at $2.55-$2.65 a share. The company also anticipated installing 180 megawatts for the period, which would be up 26% vs. the year-earlier quarter. SolarCity stock is down 57% for the year, having crashed 34% since April 22 on reports of slow residential bookings in the first quarter. In early trading on the stock market today , shares were down 3.8% at 21.01. Stock in rival Sunrun ( RUN ) was down 1.9% to 7.36. Last year, SolarCity pledged to curb its annual 80% growth rate — aiming instead for about 40% — in order to narrow its losses. Sales grew 57% in 2015, but losses also deepened to $7.91 a share from $3.88 a share for 2014.

Baidu Stock Falls On Sponsored-Post Limits; Shanghai Index Down

Baidu ’s ( BIDU ) stock fell again Monday amid a broad sell-off on Shanghai’s stock exchange after China’s biggest Internet search firm announced new measures in response to a student’s death and government probe into  health care advertising. U.S.-listed shares of Baidu fell 3.2% to 168.34 in morning trading on the stock market today . The stock tumbled 10.5% last week on the China probe, but had closed Friday just above its 200-day moving average. IBD’s Take: How healthy is Baidu’s stock and how does it compare to its peers? Find out at IBD Stock Checkup The Shanghai stock exchange fell 2.7% on Monday. Baidu said it would create a $150 million fund to fight Internet fraud and limit the number of sponsored posts to 30% of the search results page. The Cyberspace Administration of China (CAC) has reportedly set up a task force to probe Baidu amid mounting criticism over its prominent placement of sponsored health care services providers in its search results. Wei Zexi, a 21-year-old university student, died last month of a rare form of cancer. He had used the Chinese search engine to look for treatment for his cancer and later died after receiving care at a hospital he had found on Baidu search results. According to Nomura Securities , Baidu garners 20% to 30% of its  search revenue from health care. In 2010, China’s state-run television accused Baidu of promoting counterfeit drugs through its search engine.

Teva Stock Rallies After Q1 Earnings, Q2 Guidance Reassure Market

Generic and specialty drug giant Teva Pharmaceutical Industries ( TEVA ) beat analysts’ Q1 earnings estimates and guided Q2 in line with expectations Monday, sending the stock up in early trading. Teva’s Q1 earnings excluding one-time items came to $1.20 a share, down 12% from the year-earlier quarter but 3 cents above analysts’ consensus. Revenue shrank 3.5% to $4.81 billion, but that’s more than $30 million past consensus. Teva guided Q2 earnings at $1.16 to $1.20 a share, down from $1.43 a year ago and bracketing consensus. It forecast Q2 revenue to decline slightly to $4.7 billion to $4.9 billion, on the low side of analysts’ $4.89 billion. Teva stock was up 4.5% in early trading on the stock market today , near 52.50, perhaps as a relief rally after the whole industry got spooked Friday by Endo International ‘s ( ENDP ) comments about pricing pressure in generic drugs , driving it to slash its full-year guidance. Teva stock fell to a more than 18-month low of 50 on Friday. Teva declined to offer 2016 guidance until it closes its buyout of Allergan ‘s ( AGN ) generics unit Actavis, which is expected to happen next month, but its Q2 guide did not suggest a dramatic underperformance. Credit Suisse analyst Vamil Divan did note, however, that the generics business, which makes up about 45% of total revenue, missed Wall Street’s estimate, though this was balanced out by a beat on the specialty side. “U.S. Generics revenues declined 32% year over year, mainly from a decline in sales of Nexium and Pulmicort,” Divan wrote in a research note. “Specialty Medicine revenues increased by 10% year over year, driven primarily by higher sales of CNS (central nervous system) and respiratory products.” Allergan stock, which also sold off Friday, was up 4.5% in early trading Monday. Endo stock was down 2.5%.